# CollimateHealth

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/collimatehealth

- Industry: Medical Devices & Equipment
- Headquarters: Munich, Germany
- Website: www.collimatehealth.com/
- Total disclosed funding: $7M
- Latest round: Seed (May 11, 2026)
- Investors on record: 5

## About

Based in Munchen, Germany, founded in 2026, CollimateHealth GmbH focuses on advanced microbeam radiation technology for cancer treatment. The Company was co-founded by Stefan Bartzsch, Johanna Winter and Hans Maria Heyn (CEO as of 2026). In June 2026, CollimateHealth GmbH raised EUR 6 million in seed funding co-lead by Caesar Ventures, High-Tech Gruenderfonds, Positron Ventures, VP Venture Partners, and XISTA Science Ventures. 

CollimateHealth specializes in advanced microbeam radiation technology, aimed at transforming cancer treatment. Their core offering includes a clinically scalable system that delivers narrow, micrometer-scale radiation beams at higher doses than conventional methods. This innovative technology induces unique cell death in tumors while activating immune responses that target cancer cells beyond the primary site, facilitating better therapeutic delivery alongside chemotherapy and immunotherapy. The company serves oncology departments in hospitals and cancer treatment centers across North America and Europe, providing solutions designed to improve patient outcomes in cancer therapy.

CollimateHealth's revenue model is based on partnerships with healthcare institutions, including hospitals and specialized oncology clinics. The company supplies its microbeam radiation technology as part of a broader therapeutic offering through long-term agreements that involve equipment installation, maintenance, and support services. Revenue is generated through direct B2B sales of the technology and related services, reflecting the firm's focus on integrating advanced radiation therapy into existing cancer treatment protocols. The partnerships with leading academic and clinical institutions bolster its credibility and outreach within the healthcare sector.

The company Plans to use the June 2026 funding for oncology microbeam therapy prototype development and preclinical study advancement.

## Funding rounds

- Seed, May 11, 2026, $7M — High-Tech Gruenderfonds, VP Venture Partners, Xista Science Ventures, Positron Ventures, Caesar Ventures

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- VP Venture Partners (https://capitalatlas.ai/funds/vp-venture-partners) — Seed
- Xista Science Ventures (https://capitalatlas.ai/funds/xista-science-ventures) — Seed
- Positron Ventures (https://capitalatlas.ai/funds/positron-ventures) — Seed
- Caesar Ventures (https://capitalatlas.ai/funds/caesar-ventures) — Seed